Purpose: This study evaluates the feasibility of utilizing robotic-assisted bronchoscopy with cone beam computed tomography (RB-CBCT) platform to perform low-dose-rate brachytherapy implants (LDR-BT) in a mechanically ventilated human cadaveric model. Post-implant dosimetry was compared to standard stereotactic body radiation therapy plans (SBRT).
Materials And Methods: The RB-CBCT platform was used to place inert LDR-BT seeds into mechanically ventilated human cadavers with percutaneously injected pseudotumors.
Humans are excellent at modifying our behaviour depending on context. For example, humans will change how they explore when losses are possible compared to when they are not possible. However, it remains unclear what specific cognitive and neural processes are modulated when exploring in different contexts.
View Article and Find Full Text PDFIn the current study, we examine associations between exposure to violence and antiretroviral medication adherence in persons with HIV (PWH) in a southern city in the United States. We include investigation of a variety of violence exposures including childhood sexual abuse, physical abuse, witnessing family violence, lifetime violence exposures and current stress related to violence experiences, as well as neighborhood violence exposure. We examined associations between violence exposures and adherence and mediational pathways between these variables including mental health symptoms - specifically depressive, anxiety, and posttraumatic stress symptoms - as well as coping strategies.
View Article and Find Full Text PDFPurpose: This study investigated the effects of pre-operative topical moxifloxacin prior to cataract surgery on the growth of ocular surface bacteria and induced antibiotic resistance after a 3-day course of moxifloxacin.
Methods: The study was a prospective, dual arm, randomized study. The study group of 17 patients used moxifloxacin four times daily, for three days prior to surgery.
Purpose Of Review: This review highlights new Federal Drug Administration (FDA) approved glaucoma treatments to familiarize providers with immediately available options.
Recent Findings: New FDA-approved treatments include the bimatoprost implant, travoprost implant, direct selective laser trabeculoplasty (DSLT), and ocular pressure adjusting pump. The bimatoprost implant is approved for a single administration with effects lasting for about 1 year, as opposed to the nearly 3-year effect for the travoprost implant.